# Eli Lilly’s market share in the GLP-1 category of drugs dropped from 61% in March to 56% in February.

*business · news · 2026-04-09 · The Financial Express*

## Key points

- Eli Lilly’s tirzepatide brand Mounjaro sales dropped 21% in March after semaglutide generics launched.
- Novo Nordisk slashed Wegovy prices by 36% in April to match Indian generic competitors.
- Semaglutide’s market share in India’s GLP-1 segment rose from 25% in February to 33% in March.
- Twelve Indian companies launched 23 generic semaglutide brands within three weeks of patent expiry.
- Semaglutide’s patent remains valid in the US and Europe until the early 2030s.

**Companies:** Eli Lilly, Novo Nordisk
**Countries:** India, China, Canada, Brazil

[Read the full story on The Financial Express](https://www.financialexpress.com/business/healthcare/mounjaro-takes-a-hit-as-generic-weight-loss-medicines-flood-the-market/4201975/)

---

Canonical: https://newsio.io/n/59ea38d4-7e98-4391-9873-d959e0b23db9/eli-lillys-market-share-in-the-glp-1-category-of-drugs-dropped-from-61-in-march
Summarized by Newsio from The Financial Express. https://newsio.io/how-it-works